The neural stem announces the results of neural stem cell transplant studies on a mouse model of Alzheimer's disease

Germain Town, Maryland – (와이어) October 26, 2018 – Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company specializing in the development of new drugs for the treatment of the nervous system, Related research has been published in the scientific journal Scientific World Reports. According to the document, NIR-STEM has developed its own patent (US Patent No. 9,750,769) .NSI-532.IGF1, a host of human neural stem cells, has been shown to enhance the cognitive function of the murine model of Alzheimer's disease.

The study was led by a team led by Dr. Eva Feldman, director of the Neurology Research Program and director of the ALS Center of Excellence of the University of Michigan's School of Medicine. The researchers transplanted neural stem cell lines into APP / PS1 mice with the Alzheimer's disease-related mutation gene.

NSI-532.IGF1 was injected near the hippocampus, which plays a key role in the formation of brain memory. In addition, we measured the cognitive abilities of laboratory animals and the pathological condition of beta-amyloid plaques (Aβ), identified as being at the origin of Alzheimer's disease. Laboratory animals with neural stem cells improved their cognitive control-related abilities by performing two memory tasks that rely on the function of the hippocampus. In addition, control-related beta-amyloid-related pathology is impaired.

Dr. Karl Johe, Ph.D., senior scientist at Neurstem, said, "The current clinical development process for neural stem cell processing, NSI-566, is a treatment for stroke, spinal cord and Alzheimer's disease.NSI-532.IGF1 is a candidate for new generation stem cell therapy and aims to treat degenerative diseases such as Alzheimer's disease by combining stem cells Neural Factors with the Neuroprotective Protein IGF-1 This is a preclinical study conducted by Dr. Feldman's team, which suggests that the combination of neural stem cells with IGF-1 could reduce the decline cognitive and pathology due to Alzheimer's disease. "

"Alzheimer's disease is a major cause of dementia," said Dr. Feldman. "Our team has achieved interesting results by injecting human neural stem cells into a good animal model," said Dr. Feldman, "and we will continue to work with Neural System in the future."

Overview of Neuralstem

Neural stem is a clinical phase biopharmaceutical company that develops new drugs for neurological diseases with a high medical need. The two new drug candidates that we developed are as follows. NSI-566 is a candidate for neural stem cell therapy and is currently evaluating the efficacy of stroke treatment for the treatment of stroke, amyotrophic lateral sclerosis (ALS) and stroke. chronic spinal cord injury (CSCI). NSI-189 is a candidate for the development of a low molecular weight neurogenic drug for the treatment of major depressive disorder (MDD) and clinical development for the treatment of Angelman syndrome, radiation-induced cognitive impairment, type 1 diabetes, type 2 diabetes, and stroke. Neural's diverse portfolio of drug candidates is based on its own neural stem cell technology.

Disclaimer Regarding Forward-Looking Statements

This press release contains forward-looking statements based on the exclusion clause of the Private Securities Litigation Reform Act, 1995. These forward-looking statements relate to events that will occur in the future rather than in the past, such as "expected", "expected", "expected", "planned", "believed", "continued", Lt; / RTI & gt; Forward-looking statements include various uncertainties because of their nature. Risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements include, but are not limited to, the risks inherent in the development and commercialization of the product, uncertainties related to the results of clinical trials or regulatory approvals, the requirements additional own funds, And dependence on others. Actual results may differ from those anticipated by the forward-looking statements. Additional information that may affect various results, other risks, and uncertainties can be found in the periodic neural trunk reports submitted to the SEC, including the 10K annual report (December 31, 2017). . Respectively. The company has no obligation to update the forward-looking statements.

This news is a press release distributed by companies, organizations and organizations via News Wire. Deployment Guide